Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025) have been officially released, with significant inclusions for certain drugs [1] Group 1: Drug Catalog Updates - The drug "Dihydropyridine Linalool Ester Capsules" has been successfully included in the new drug catalog [1] - "Senapali Capsules" and "Zevokiorunsai Injection" (Sikaze®), both exclusively commercialized by East China Pharmaceutical, have also been added to the new drug catalog and the first commercial health insurance innovative drug catalog [1] - East China Pharmaceutical now has a total of three innovative drug products included in either the new drug catalog or the first commercial health insurance innovative drug catalog [1] Group 2: Implementation and Impact - The new catalog will be fully implemented starting January 1, 2026, allowing more ovarian cancer patients in China to access affordable treatment options [1]

Group 1: Aier Eye Hospital - In 2024, Aier Eye Hospital achieved an outpatient volume of 16.94 million, a year-on-year increase of 12.14% [1] - The company reported a total revenue of 20.98 billion yuan, reflecting a growth of 3.02% compared to the previous year [2] - The net profit attributable to shareholders was 3.56 billion yuan, up by 5.87% year-on-year [2] - The company introduced several advanced medical technologies and products, including the INTENSITY™ intraocular lens and new dry eye treatment technology [1][3] Group 2: Tonghuashun - Tonghuashun reported a revenue of 4.19 billion yuan in 2024, marking a 17.47% increase from the previous year [5] - The net profit attributable to shareholders reached 1.82 billion yuan, a significant growth of 30% year-on-year [4][5] - The increase in revenue and profit was primarily driven by a recovery in the securities market and rising demand for financial information services [4] Group 3: Yiwei Lithium Energy - Yiwei Lithium Energy achieved a revenue of 1.28 billion yuan in Q1 2025, with a net profit of 110.11 million yuan, reflecting a 16.60% increase in net profit [7] - The company reported a significant increase in the shipment of energy storage batteries, with a year-on-year growth of 80.54% [8] - The company is expanding into emerging markets such as eVTOL and drones, with ongoing projects and production facilities being established [9] Group 4: Huadong Medicine - Huadong Medicine reported a revenue of 10.74 billion yuan in Q1 2025, a 3.12% increase year-on-year [10] - The net profit attributable to shareholders was 914.71 million yuan, up by 6.06% compared to the same period last year [11] - The company achieved its highest historical level of net profit excluding non-recurring gains and losses, reaching 897.34 million yuan [10] Group 5: Muyuan Foods - Muyuan Foods reported a revenue of 36.06 billion yuan in Q1 2025, a year-on-year increase of 37.26% [17] - The company turned a profit with a net profit of 44.91 billion yuan, compared to a loss of 23.79 billion yuan in the same period last year [18] - The significant growth was attributed to increased pig prices and sales [17] Group 6: China Aluminum - China Aluminum reported a revenue of 55.78 billion yuan in Q1 2025, with a net profit of 3.54 billion yuan, reflecting a year-on-year increase of 58.78% [21] - The company successfully managed market price fluctuations, resulting in increased product sales and profits [21] Group 7: Hengrui Medicine - Hengrui Medicine achieved a revenue of 72.06 billion yuan in Q1 2025, a 20.14% increase year-on-year [22] - The net profit attributable to shareholders was 18.74 billion yuan, up by 36.9% compared to the previous year [22] - The increase in profit was significantly influenced by a licensing payment received during the reporting period [22] Group 8: Bull Group - Bull Group reported a revenue of 16.83 billion yuan in 2024, reflecting a 7.24% increase year-on-year [13] - The net profit attributable to shareholders was 4.27 billion yuan, a growth of 10.39% compared to the previous year [13] - The company experienced growth in its electrical connection and smart lighting businesses, as well as rapid development in its new energy sector [14]

Core Insights - The company reported a total revenue of approximately 41.91 billion yuan in 2024, representing a year-on-year increase of 3.16% compared to 40.62 billion yuan in 2023 [1] - The pharmaceutical industry is experiencing significant growth driven by the introduction of new products into the medical insurance catalog, with notable sales increases in innovative drugs and biosimilars [3] - The company has established a strong market presence in specialized chronic disease treatment areas, maintaining a leading market share in various therapeutic fields [3] Revenue Breakdown - Total revenue for 2024 was 41.91 billion yuan, with the commercial sector contributing 28.47 billion yuan (67.94% of total revenue), and the manufacturing sector contributing 15.78 billion yuan (37.65% of total revenue) [1] - The medical beauty business generated 2.33 billion yuan, showing a decline of 4.94% from the previous year [1][8] - Internal sales accounted for 97.39% of total revenue, while external sales made up 2.61%, with external sales decreasing by 23.29% year-on-year [1] Product and Market Development - The company has a comprehensive pipeline of over 20 products in the diabetes treatment sector, covering various clinical mainstream targets [4] - In the field of autoimmune diseases, the company has over 20 products in development, with a focus on a wide range of conditions [4] - The medical beauty segment is expected to stabilize and grow, with the company actively expanding its global market presence through subsidiaries [8] Financial Performance - The core subsidiary, China Medical East, achieved sales revenue of 13.81 billion yuan, a year-on-year increase of 13.05%, and a net profit of 2.88 billion yuan, up 29.04% [5] - The pharmaceutical commercial segment reported revenue of 27.09 billion yuan, a slight increase of 0.41%, with a net profit of 456 million yuan, up 5.58% [7] - The industrial microbiology segment saw a significant revenue increase of 43.12%, with various sub-segments experiencing substantial growth [8]